Abstract
Glioblastoma multiforme (GBM) is the most aggressive brain tumor in adults. The median survival period of patients with GBM is approximately twelve months. Radiation therapy plus temozolomide, the current standard therapy, has generally failed to prevent recurrence of GBM. The efficacy of chemotherapy for the recurrent GBM is limited. The phase II trial of bevacizumab, an anti-vascular endothelial growth factor antibody, and irinotecan reports the efficacy for the recurrent GBM. We report a patient with recurrent GBM who responded very well to the chemotherapy consisting of bevacizumab and irintoecan. Bevacizumab and irinotecan may improve the treatment outcome of patients with recurrent GBM.
